Market Spotlight: Acute Decompensated Heart Failure (ADHF)


Report
28 Pages
March 2021
Region: Global
Citeline
ID: 4775258

This Market Spotlight report covers the Acute Decompensated Heart Failure (ADHF) market, comprising key marketed and pipeline drugs, upcoming events, clinical trials, probability of success, and epidemiology information.

Key Takeaways

Approved drugs in the acute decompensated heart failure (ADHF) space target natriuretic peptide receptors, phosphodiesterase 3, potassium channels, and troponin-C. All of the approved therapies are administered via the intravenous route, with two drugs also being available in an oral formulation.
The greatest proportion of industry-sponsored drugs in active clinical development for ADHF are in Phase I. Therapies in development for ADHF focus on targets such as Na-K-Cl cotransporter, guanylate cyclase, ryanodine receptor, sarcoplasmic reticulum Ca2+-ATPase, troponin, beta-3 adrenergic receptor, vasopressin receptors, and relaxin family peptide receptors 1–4. These therapies are administered via the oral, intravenous, and subcutaneous routes.
High-impact upcoming events for drugs in the ADHF space comprise topline Phase II trial results for istaroxime, topline Phase IIa trial results for APD418, and topline Phase IIb trial results for cimlanod.
The overall likelihood of approval of a Phase I ADHF asset is 1.6%, and the average probability a drug advances from Phase III is 28.6%. Drugs, on average, take 12.9 years from Phase I to approval, compared to 10.1 years in the overall cardiovascular space.
The distribution of clinical trials across Phase I–IV indicates that the majority of trials for ADHF have been in the late phases of development, with 58% of trials in Phase III–IV, and 42% in Phase I–II.
Clinical trial activity in the ADHF space is dominated by completed trials. Johnson & Johnson has the highest number of completed clinical trials for ADHF, with 17 trials.
Johnson & Johnson leads industry sponsors with the highest overall number of clinical trials for ADHF, followed by Novartis

OVERVIEWKEY TAKEAWAYS

DISEASE BACKGROUND

Definition
Symptoms
Patient subtypes
Risk factors
Diagnosis

TREATMENT

Diuretics
Vasodilator therapy
Ultrafiltration (UF)
Inotropes
Natriuretic peptides
Vasopressors/Beta blockers/ACE inhibitors
Circulatory assist devices
Other therapies

EPIDEMIOLOGY

ADHF incidence

MARKETED DRUGSPIPELINE DRUGSKEY UPCOMING EVENTSPROBABILITY OF SUCCESS

CLINICAL TRIAL LANDSCAPE

Sponsors by status
Sponsors by phase

BIBLIOGRAPHY

Prescription information

APPENDIX

LIST OF FIGURES

Figure 1: Overview of pipeline drugs for ADHF in the US
Figure 2: Pipeline drugs for ADHF, by company
Figure 3: Pipeline drugs for ADHF, by drug type
Figure 4: Pipeline drugs for ADHF, by classification
Figure 5: Key upcoming events in ADHF
Figure 6: Probability of success in the ADHF pipeline
Figure 7: Clinical trials in ADHF
Figure 8: Top 10 drugs for clinical trials in ADHF
Figure 9: Top 10 companies for clinical trials in ADHF
Figure 10: ADHF trials status
Figure 11: ADHF trials sponsors, by phase

LIST OF TABLES

Table 1: Marketed drugs for ADHF
Table 2: Pipeline drugs for ADHF in the US

Table of Contents

Related Topics

Related Reports

Heart Failure Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

Congestive Heart Failure (CHF) Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts - 2023 to 2031

Acute Heart Failure (AHF) Therapeutics: Global Strategic Business Report

Heart Failure Epidemiology Analysis and Forecast to 2032

Acute Heart Failure Therapeutics Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application